Pre-operative Endocrine Therapy.

about

Pre-operative Endocrine Therapy.

Item

http://www.wikidata.org/entity/Q46143861

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pre-operative Endocrine Therapy.

@en

Pre-operative Endocrine Therapy.

@nl

type

Item

label

Pre-operative Endocrine Therapy.

@en

Pre-operative Endocrine Therapy.

@nl

prefLabel

Pre-operative Endocrine Therapy.

@en

Pre-operative Endocrine Therapy.

@nl

P1476

Pre-operative Endocrine Therapy.

@en

P2093

Arran K Turnbull

http://www.w3.org/2001/XMLSchema#string

J Michael Dixon

http://www.w3.org/2001/XMLSchema#string

Laura M Arthur

http://www.w3.org/2001/XMLSchema#string

Lucy R Khan

http://www.w3.org/2001/XMLSchema#string

P2860

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)

The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study

Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

P2888

s12609-017-0255-6

P304

202-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S12609-017-0255-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29201277

http://www.w3.org/2001/XMLSchema#string

P932

5694502

http://www.w3.org/2001/XMLSchema#string